Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 47Genitourinary 15CNS 7Dermatologic 6Thoracic 3Sarcoma 3Other hematologic neoplasm 3Breast 2Tumor-Agnostic 1Other solid neoplasm 1Other neoplasm 1

Conditions

Breast Neoplasms 2Pathologic Complete Response 1

Interventions

Cyclophosphamide 423Trastuzumab 414Paclitaxel 375Docetaxel 314Capecitabine 266Letrozole 262Carboplatin 257Doxorubicin 213Tamoxifen 184Fulvestrant 176Epirubicin 176Radiotherapy 171Anastrozole 164pembrolizumab 152pertuzumab 147Surveys and Questionnaires 146Exercise 142exemestane 128Vinorelbine 127palbociclib 124Bevacizumab 123Magnetic Resonance Spectroscopy 120Blood Specimen Collection 120Drug Therapy 106Albumin-Bound Paclitaxel 105Gemcitabine 99130-nm albumin-bound paclitaxel 98pyrotinib 92eribulin 90Biopsy 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Vinblastine × Breast × Clear all
NCT02299999 2025-01-15

SAFIR02_Breast

UNICANCER

Phase 2 Active not recruiting
1,460 enrolled
Breast

Breast Neoplasms

NCT04781725 2021-11-17

INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer

Ottawa Hospital Research Institute

Phase 2 Unknown
90 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡